Evidence mapPaperPMID 41373858Full record

ReviewInternational journal of molecular sciences2025

Decoding the Kruppel-like Transcription Factors in Atherosclerosis: Insight from Molecular and Translational Perspectives.

Yiyang Cao, Chenyue Wang, Xuzhou Zhu, Meiqian Zhan, Jinhui Xu, Meixiu Jiang

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yiyang CaoThe Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.ORCID 0009-0004-0061-6494
Chenyue WangThe Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
Xuzhou ZhuThe Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.ORCID 0009-0000-7207-3223
Meiqian ZhanThe Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
Jinhui XuThe Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
Meixiu JiangJiangxi Province Key Laboratory of Bioengineering Drugs, The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.

Funding

Health Commission of jiangxi province 202311127National Natural Science Foundation of China 82160094, 82200509Natural Science Foundation of Jiangxi Province 20252BAC240143the Jiangxi Province Key Laboratory of bioengineering drugs 2024SSY07061
6 · The paper itself

Abstract

Atherosclerosis is a leading contributor to cerebrovascular and cardiovascular diseases, which can be driven by multiple pathological processes, including chronic inflammation, lipid dysregulation, and vascular remodeling. Currently, lifestyle intervention and pharmacological intervention, like statins, are recommended in clinical treatments. However, the mortality and morbidity rates caused by atherosclerosis remain high. Kruppel-like transcription factors (KLFs) are zinc-finger-containing transcription factors that are involved in various physiological and pathological processes. By modulating endothelial cell homeostasis, smooth muscle cell phenotypic switching, and inflammatory responses, members of the KLF family-particularly KLF2, KLF4, KLF5, KLF6, and KLF14-emerge as pivotal regulators in the initiation and progression of atherosclerotic lesions. In this review, we constructed a comprehensive network of KLFs in the pathogenesis of atherosclerosis. Based on the molecular mechanism, this review for the first time highlighted newly identified substances that exploit KLF-modulated pathways to attenuate atherosclerosis, and discussed emerging gene therapy and nanotechnology approaches, addressing both the therapeutic promise and challenges associated with targeted KLF modulation. This first offered new avenues for translational and precision medicine in atherosclerotic cardiovascular disease from the perspective of KLF.

Indexed as

AtherosclerosisKruppel-Like Transcription FactorsAnimalsHumansKruppel-Like Factor 4Translational Research, BiomedicalKLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription Factorsatherosclerosisclinical treatmentKruppel-like transcription factors

Identifiers

PMID41373858
PMCPMC12692229

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.